Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07053800 | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis | PHASE2 | RECRUITING | 35 | — | — | Jan 16, 2026 | Oct 1, 2029 | Apr 27, 2026 | 26 | United States, Brazil +1 |
CRR is defined as change in * urine protein creatinine ratio (UPCR) and * estimated glomerular filtration rate (eGFR) and * without use of rescue medication
| Arm | Type | Description |
|---|---|---|
| Obe-cel | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Obecabtagene autoleucel | BIOLOGICAL | Obecabtagene autoleucel (obe-cel) given as a single infusion |
Inclusion Criteria: * Willing and able to give written informed consent for participation in the study or written informed consent signed by a legal guardian or representative * Ability and willingness to adhere to protocol's Schedule of Activities and other requirements * Participants must be 12 t...